Zevra Therapeutics (ZVRA) Asset Writedowns and Impairment (2024 - 2026)

Zevra Therapeutics has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $500000.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $500000.0; the trailing twelve-month figure through Mar 2026 stood at $59.2 million (up 1038.29% YoY), and the FY2025 full-year result was $11.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $500000.0, up from -$19000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $58.7 million in Q2 2025, with the low at -$19000.0 in Q4 2025.
• Historically, Asset Writedowns and Impairment has averaged $12.9 million across 3 years, with a median of $2.0 million in 2024.
• The largest YoY upside for Asset Writedowns and Impairment was 1734.69% in 2025 against a maximum downside of 1734.69% in 2025.
• Zevra Therapeutics' Asset Writedowns and Impairment stood at $2.0 million in 2024, then tumbled by 100.95% to -$19000.0 in 2025, then surged by 2731.58% to $500000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $500000.0 (Q1 2026), -$19000.0 (Q4 2025), and $58.7 million (Q2 2025), per Business Quant data.